Literature DB >> 24928450

Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms.

Christine Anne Ganzer1, Alan Roy Jacobs2, Farin Iqbal2.   

Abstract

Finasteride is a synthetic 5-α reductase inhibitor, which prevents the conversion of testosterone to dihydrotestosterone and has been used for more than 20 years in the treatment of male pattern hair loss. Randomized, controlled trials have associated finasteride with both reversible and persistent adverse effects. In this pilot study, we sought to characterize sexual and nonsexual adverse effects that men reported experiencing at least 3 months after stopping the medication. Based on previous research on persistent side effects of finasteride, we constructed an Internet survey targeting six domains: physical symptoms, sexual libido, ejaculatory disorders, disorders of the penis and testes, cognitive symptoms, and psychological symptoms and was e-mailed to patients who reported experiencing symptoms of side effects of finasteride. Responses from 131 generally healthy men (mean age, 24 years) who had taken finasteride for male pattern hair loss was included in the analysis. The most notable finding was that adverse effects persisted in each of the domains, indicating the possible presence of a "post-finasteride syndrome."
© The Author(s) 2014.

Entities:  

Keywords:  andrology; behavioral research; cognitive performance; erectile dysfunction; sexual health

Mesh:

Substances:

Year:  2014        PMID: 24928450     DOI: 10.1177/1557988314538445

Source DB:  PubMed          Journal:  Am J Mens Health        ISSN: 1557-9883


  29 in total

Review 1.  Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome.

Authors:  Raymond Fertig; Jerry Shapiro; Wilma Bergfeld; Antonella Tosti
Journal:  Skin Appendage Disord       Date:  2016-09-23

2.  Association of Suicidality and Depression With 5α-Reductase Inhibitors.

Authors:  Blayne Welk; Eric McArthur; Michael Ordon; Kelly K Anderson; Jade Hayward; Stephanie Dixon
Journal:  JAMA Intern Med       Date:  2017-05-01       Impact factor: 21.873

Review 3.  Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?

Authors:  Silvia Giatti; Silvia Diviccaro; Giancarlo Panzica; Roberto Cosimo Melcangi
Journal:  Endocrine       Date:  2018-04-19       Impact factor: 3.633

4.  Emotional Consequences of Finasteride: Fool's Gold.

Authors:  Christine Anne Ganzer; Alan Roy Jacobs
Journal:  Am J Mens Health       Date:  2016-02-11

5.  Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases.

Authors:  Nicolò Schifano; Paolo Capogrosso; Luca Boeri; Giuseppe Fallara; Stefania Chiappini; Matthew Rewhorn; Omer Onur Cakir; Hannah Harvey; Fabio Castiglione; Hussain M Alnajjar; Asif Muneer; Federico Deho'; Fabrizio Schifano; Francesco Montorsi; Andrea Salonia
Journal:  Int J Impot Res       Date:  2022-05-05       Impact factor: 2.896

6.  Short-Term Efficacy of Autologous Cellular Micrografts in Male and Female Androgenetic Alopecia: A Retrospective Cohort Study.

Authors:  Shadi Zari
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-11-19

7.  How to Deal with the Issues of Fertility, Malignancies, and the Postfinasteride Syndrome while Prescribing Finasteride for Male Pattern Hair Loss.

Authors:  Ralph M Trüeb; Ngoc-Nhi Catharina Luu; Maria Fernanda Reis Gavazzoni Dias; Hudson Dutra Rezende
Journal:  Skin Appendage Disord       Date:  2022-01-10

8.  Characteristics of Men Who Report Persistent Sexual Symptoms After Finasteride Use for Hair Loss.

Authors:  Shehzad Basaria; Ravi Jasuja; Grace Huang; Whitney Wharton; Hong Pan; Karol Pencina; Zhuoying Li; Thomas G Travison; Jag Bhawan; Renaud Gonthier; Fernand Labrie; Alain Y Dury; Carlo Serra; Allen Papazian; Michael O'Leary; Sami Amr; Thomas W Storer; Emily Stern; Shalender Bhasin
Journal:  J Clin Endocrinol Metab       Date:  2016-09-23       Impact factor: 5.958

9.  Urinary Amine Metabolomics Characterization with Custom 12-Plex Isobaric DiLeu Labeling.

Authors:  Pingli Wei; Ling Hao; Samuel Thomas; Amanda Rae Buchberger; Laura Steinke; Paul C Marker; William A Ricke; Lingjun Li
Journal:  J Am Soc Mass Spectrom       Date:  2020-08-04       Impact factor: 3.109

10.  Alterations of gut microbiota composition in post-finasteride patients: a pilot study.

Authors:  F Borgo; A D Macandog; S Diviccaro; E Falvo; S Giatti; G Cavaletti; R C Melcangi
Journal:  J Endocrinol Invest       Date:  2020-09-19       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.